![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Takeda Announces Withdrawal of Marketing Authorization Application for Peginesatide Injection in Europe
Takeda Announces Withdrawal of Marketing Authorization Application for Peginesatide Injection in Europe
July 1, 2013
Takeda’s European subsidiary, Takeda Development Centre Europe, has withdrawn its marketing authorization application for injectable peginesatide solution, aimed at treating anemia in patients with kidney disease.
Takeda
Takeda
Upcoming Events
-
21Oct